For patients with psoriasis, vitiligo, atopic dermatitis (AD), and chronic urticaria (CU), COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease.
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Researchers sought to determine the percentage of patients with psoriasis who contracted COVID-19 while receiving apremilast.
Researchers conducted a study to assess the safety and efficacy of levamisole in individuals with loiasis parasitic infection.
Investigators conducted a study to determine the effects of quinine hydrochloride in combination with antimicrobial blue light therapy in patients with cutaneous mold infection.
Researchers sough to assess the relationship between CD4/CD8 ratios and the risk for Kaposi sarcoma and non-Hodgkin lymphoma among patients with HIV infection treated with combination antiretroviral therapy.
Clindamycin phosphate EQ 1% gel is indicated for topical application in the treatment of acne vulgaris.
Risk for postoperative wound infection, complications, hemorrhage no greater with adalimumab versus placebo in hidradenitis suppurativa.
Investigators conducted a retrospective cohort study of chilblains as a possible cutaneous manifestation of COVID-19.
The rates of SARS-CoV-2 infection, hospitalization, and mortality in patients with or without AD are compared.
